GlassScriptPhysician profile
Peace Okorie
NPI 1124382767
$5,870.52
in general payments reported to CMS, 2019-2025
49 companies · $811 in 2025
The $811 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $2,627 · 2023: $704 · 2024: $1,394 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.42 |
| Education | $406.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $856.76 | 2021-2025 | Rybrevant, Carvykti, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $318.01 | 2022-2023 | Ninlaro |
| Beigene USA, INC. | $300.25 | 2022-2024 | Brukinsa |
| Pfizer INC. | $259.89 | 2021-2025 | |
| Gilead Sciences, INC. | $257.28 | 2022-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $243.04 | 2021-2025 | |
| Daiichi Sankyo INC. | $233.20 | 2022-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $219.70 | 2021-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $211.01 | 2021-2022 | |
| Incyte Corporation | $197.84 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $194.00 | 2022-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $183.39 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Seagen INC. | $170.59 | 2021-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $151.75 | 2022-2025 | Libtayo |
| Celgene Corporation | $130.36 | 2021-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $126.39 | 2023 | Vegzelma |
| Genentech USA, INC. | $115.09 | 2022-2024 | Lunsumio, Polivy, Columvi |
| Taiho Oncology, INC. | $114.51 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.18 | 2022-2025 | |
| Lilly USA, LLC | $110.65 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Inari Medical, INC. | $97.58 | 2022 | |
| Alexion Pharmaceuticals, INC. | $95.84 | 2021-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $82.88 | 2022-2024 | Tavalisse, Rezlidhia |
| Eisai INC. | $81.28 | 2021-2024 | |
| Eagle Pharmaceuticals, INC. | $79.45 | 2023 | |
| Amgen INC. | $75.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.91 | 2024 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $65.59 | 2022-2025 | Padcev |
| Abbvie INC. | $63.33 | 2022-2024 | |
| Organon LLC | $59.28 | 2022-2024 | |
| Tempus Ai, INC | $57.15 | 2025 | Xt Cdx |
| Caris Mpi, INC. | $42.92 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $42.03 | 2022-2024 | |
| Array Biopharma INC | $41.84 | 2022-2025 | Lorbrena |
| Morphosys, US INC. | $37.37 | 2021-2024 | Monjuvi |
| Foundation Medicine, INC. | $36.10 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $36.06 | 2022-2024 | Givlaari |
| Pharmaessentia USA Corporation | $33.07 | 2024 | Besremi |
| Genmab U.S., INC. | $31.76 | 2025 | Epkinly |
| Myriad Genetic Laboratories, INC. | $27.02 | 2022 | |
| Kite Pharma, INC. | $25.59 | 2025 | Yescarta |
| Genzyme Corporation | $24.35 | 2022 | |
| Mirati Therapeutics, INC. | $24.31 | 2024 | Krazati |
| G1 Therapeutics, INC. | $24.15 | 2022 | |
| Stemline Therapeutics INC. | $23.83 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $21.79 | 2022 | |
| Acrotech Biopharma INC. | $21.65 | 2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $20.14 | 2024 | Rolvedon |
| Global Blood Therapeutics, INC. | $18.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peace Okorie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.